On February 14, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) (Press release, Aura Biosciences, FEB 14, 2022, View Source [SID1234608091]). The results will be presented as part of the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary (GU) Cancer Symposium being held February 17-19 in San Francisco, CA and online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Non-muscle invasive bladder cancer remains an area of high unmet need with high levels of recurrence and progression and no approved targeted therapies. We believe that AU-011’s mechanism of action supports its potential use as a front-line treatment following initial diagnosis and/or for Bacillus Calmette-Guerin (BCG) refractory disease," said Dr. Cadmus Rich, Chief Medical Officer and Head of R&D of Aura Biosciences. "These preclinical data further support AU-011’s potential in treating urothelial cancer, including NMIBC. We look forward to initiating our planned Phase 1 clinical trial in the second half of this year.
Demonstration of AU-011 Applicability in Urothelial Cancer
Using a panel of human bladder cancer cell lines that represent different stages of the disease, AU-011 demonstrated consistent tumor cell binding and cytotoxicity in vitro. These data support that AU-011’s targeting of bladder cancer cells through HSPGs is tumor grade agnostic. Tumor binding and distribution of AU-011 was evident in both ex vivo human bladder cancer tissues and in an in vivo murine bladder cancer model. Collectively, these results support further investigation of the use of AU-011 in patients with urothelial neoplasia.
Details for the poster presentation are as follows:
Title: Targeting Urothelial Neoplasia Using an Investigational Virus-Like Drug Conjugate
Presenter: Rhonda C. Kines, Aura Biosciences
Poster Session: Urothelial Carcinoma, poster #514
Date and time: Friday, February 18 at 3:30 PM PT
Location: On Demand
The poster can be accessed by visiting the "Scientific Presentations" section of "VDC Platform" page of the Aura Biosciences website.